Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
44 hedge funds and large institutions have $36.6M invested in Viracta Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 5 reducing their positions, and 5 closing their positions.
469% more capital invested
Capital invested by funds: $6.42M → $36.6M (+$30.1M)
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
160% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 5
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
30% more call options, than puts
Call options by funds: $86K | Put options by funds: $66K
10% more funds holding
Funds holding: 40 → 44 (+4)
3.31% more ownership
Funds ownership: 41.23% → 44.54% (+3.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aisling Capital Management
New York
|
+$3.24M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$2.43M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$2.4M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$570K |
| 5 |
FI
Fosun International
Hong Kong,
China
|
+$469K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$166K |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$132K |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$62.2K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$56K |
| 5 |
Two Sigma Investments
New York
|
-$15K |
VIRX Hedge Fund Activity: Q1 2019 in Review
44 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q1 2019, worth a combined $36.6M — up 469% from $6.42M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new VIRX positions and 5 closed out — a net gain of 4 holders — while 13 added to existing stakes and 5 trimmed.
The largest buyer was Aisling Capital Management, adding an estimated $3.24M. The largest seller was Sabby Management, exiting entirely with an estimated $166K sold.
- 44 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q1 2019, up from 40 in Q4 2018.
- Funds reported $36.6M of Viracta Therapeutics, Inc. Common Stock stock for Q1 2019, up 469% quarter-over-quarter.
- 9 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q1 2019 and 5 closed out, a net change of +4 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q1 2019 was Aisling Capital Management, an estimated $3.24M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q1 2019 was Sabby Management, an estimated $166K sold.
Based on aggregated 13F filings for Q1 2019.